Clinical Trial Update: A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing Nanogen's darbepoetin alfa with Amgen's Aranesp in anemia due to chronic kidney disease in patients on dialysis. The study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)
• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Conditions: Anemia, Chronic Kidney Disease Requiring Chronic Dialysis | Phase 3 | Status: COMPLETED